Polynovo Limited · ASX:PNV
Polynovo — ASX CEO Sessions April 2017
24 slides from Polynovo's conference presentation, Apr 11, 2017
Slide 1: ASX CEO Sessions, PolyNovo Presentation
PolyNovo Limited ABN 96 083 866 862 2/320 Lorimer Street, Port Melbourne VIC 3207 Tel: +61 3 8681 4050 Fax: +61 3 8681 4099 11 April 2017 For personal use only ASX CEO Sessions, PolyNovo Presentation PolyNovo Limited is pleased to release the presentation to be given by CEO Paul Brennan today at the
Slide 2: PolyNovo Market Update
For personal use only PolyNovo Market Update Paul Brennan ASX CEO sessions April 2017
Slide 3: Disclaimer
Disclaimer For personal use only This presentation has been prepared by PolyNovo Limited and is provided for general information purposes only. No party other than PolyNovo has authorised or caused the issue of this document, or takes responsibility for, or makes any statements, representations or u
Slide 4: Corporate Overview
Corporate Overview For personal use only Key Milestones 2004 PolyNovo incorporated ex-CSIRO Share price 5 year graph 2006 NovoSkin feasibility study 2008 Port Melbourne facility established 2010 NovoSkin is incorporated Bio-Innovation SA grant ($217K) 2011 Feasibility study on NovoPore NPWT 2013 Fir
Slide 5: NovoSorb Polymer - the basis of our product range
NovoSorb NovoSorb™ Polymer - the basis of our product range For personal use only NovoSorb • Developed by the CSIRO and spun out as PolyNovo. Listed on the ASX 2004 • Unique attribute is that the Polyurethane is made with no aromatic isocyanates or solvents • Excellent biocompatibility, safety and t
Slide 6: BTM Product Description
BTM Product Description For personal use only BTM is a fully synthetic, biodegradable dressing with 3 layers: • Sealing membrane A temporary, transparent, polyurethane sealing membrane designed to physiologically ‘close’ the wound limiting water loss/evaporation • Bonding layer A temporary PU bondin
Slide 7: PolyNovo Resource Expansion
PolyNovo Resource Expansion For personal use only • Cleanroom expansion will be complete June 2017. Provides 60% increase of space enabling improved process flow, higher production volumes, improved efficiency and waste reduction • Melbourne team expanded to 24.2 FTE over past two years, with greate
Slide 8: BTM on Sale: US
BTM on Sale For personal use only US • BTM in use in 5 states of US, more to come on stream in coming months • Progressing through the hospital procurement committees/process and staff education on use and care of the BTM. We anticipate a step change in sales in the coming months. • Initial surgeon
Slide 9: BTM on Sale: Australia & New Zealand
BTM on Sale For personal use only Australia & New Zealand • Device Technologies (DT) exclusive distribution agreement, sales made • DT have a dedicated plastic surgery sales team, BTM has been used already • NZ registration with sales available through all District Health Board • Australia sales thr
Slide 10: BTM on Sale: South Africa and other African Countries
BTM on Sale For personal use only South Africa and other African Countries • SA health system transforming to full public access scheme over the next 2 years • Ascendis Medical subsidiary, Surgical Innovations, is our exclusive distributor • 5 dedicated BTM sales representatives, experienced in the
Slide 11: BTM Application and Integration
BTM Application and Integration How BTM works For personal use only BTM only applied to a surgically debrided wound bed 1 The wound is ‘physiologically closed’, limiting contraction and risk of infection. BTM fully integrated 2 The dermis is regenerated within the scaffold/foam. Once fully integrate
Slide 12: BTM - Necrotizing Fasciitis
BTM - Necrotizing Fasciitis For personal use only Graft 4 weeks BTM applied Ready to graft Day 62 post-graft Fully debrided flank ribs exposed 2 weeks post-graft Page 11
Slide 13: Necrotizing Fasciitis, Neck
Necrotizing Fasciitis, Neck For personal use only Day 77, full range of movement; published ePlasty Page 8
Slide 14: BTM Over Bone
For personal use only BTM Over Bone Page 9
Slide 15: Allows for Staged Grafting
Allows for Staged Grafting For personal use only Note the maturity of this graft 7 days post- application. The mesh spaces are closed. A truly outstanding result. Pt 5 Day 38 post-BTM Pt 5 Day 31 post-BTM Page 14
Slide 16: Outcomes - the first Burn patients
Outcomes -the first 5 Burn patients For personal use only Pt 1 Day 536 Pt 2 Day 368 Pt 3 Day 312 Pt 4 Day 171 Pt 5 Day 194 Page 15
Slide 17: Outcomes - supple skin, elasticity
Outcomes- supple skin, elasticity For personal use only Video Day 194 Video Day 369 Page 16
Slide 18: CE Mark Trial Update
CE Mark Trial Update For personal use only A CE Mark is a regulatory standard/requirement for many countries eg: Europe, Australia, SE-Asia. Clinical trails are required as part of a Class III certification • PolyNovo require 30 burn patients within the trial • Outcomes: – BTM take, skin graft take,
Slide 19: BARDA PMA Trial Programs
BARDA PMA Trial Programs For personal use only BARDA is a US Federal agency within the Department of Human & Health Services. They are charged with preparing for mass disaster management. BARDA awarded PolyNovo a contract which funds our US based clinical trials program. Success in these trials will
Slide 20: New Product Pipeline
New Product Pipeline For personal use only Product BTM Breast Sling Hernia Breast form Skin Depots Wounds & Burns Regulatory FDA 510(k) cleared US FDA PMA clinical trials US FDA 510(k) US FDA510(k) PNV Polymer & BTM predicates supplier. Regulatory CE approval est 2018 CE standard non-clinical & CE C
Slide 21: Board and Senior Executive
Board and Senior Executive For personal use only David Williams – Chairman Mr Williams was appointed as a Non-Executive Director on 28 February 2014 and Chairman on 13 March 2014. Mr Williams is an experienced Director and Investment Banker with a proven track record in business development and stra
Slide 22: Board and Senior Executive (continued)
Board and Senior Executive (continued) For personal use only Philip Powell – Non Executive Director Mr Powell was appointed a Non-Executive Director on 13 May 2014. Mr Powell has over 18 years’ experience in investment banking specialising in capital raisings, IPOs, mergers and acquisitions and othe
Slide 23: PolyNovo - The Australian Team
PolyNovo - The Australian Team For personal use only
Slide 24: PolyNovo - Triathlon Team
PolyNovo - Triathlon Team For personal use only